RecruitingNCT06526208
Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults
Medication studyAges 18–45United States
Understand this study
Who could participate?
Listed age limits: 18 years to 45 years.
- Listed locations
- PhoenixSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 28, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 108
- Sponsor
- Southwest Autism Research & Resource Center
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT06526208
- Official title
Show the full official title
Phase 2 Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of an Oral Marijuana-Based Investigational Medical Product to Treat Anxiety in Adults With Autism Spectrum Disorder (ASD)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Phoenix
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Southwest Autism Research & Resource Center.
Does this study involve medication?
Yes. The study involves medication, including MB-IMP.
Who can participate?
Listed age limits: 18 years to 45 years.
Is this study still recruiting?
The registry lists this study as recruiting.
